Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Qingyong Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8977-320X; OpenAlex author ID A5015888710. Sources: OpenAlex.

Their work

Papers
109 (first author 11, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
132
Papers, trials and grants by year

2011: 7 papers · 2012: 7 papers · 2013: 10 papers · 2014: 9 papers · 2015: 7 papers · 2016: 10 papers · 2017: 5 papers · 2018: 13 papers · 2019: 8 papers · 2020: 8 papers · 2021: 3 papers · 2022: 14 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers

Papers 50 of 109

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  2. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  3. Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin. Co-author DOI 10.18332/tid/203455↗
  4. Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing S… Co-author DOI 10.1016/j.canlet.2023.216602↗
  5. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis. Co-author DOI 10.1016/j.cellsig.2024.111381↗
  6. A qualitative study on the disease coping experiences of pancreatic cancer patients and their spouses. Co-author DOI 10.1038/s41598-024-69599-7↗
  7. Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Last author DOI 10.1007/s00210-023-02499-1↗
  8. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215976↗
  9. NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. Co-author DOI 10.1002/1878-0261.13230↗
  10. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Last author DOI 10.1007/s00210-022-02203-9↗
  11. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  12. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing … Co-author DOI 10.1016/j.canlet.2022.215913↗
  13. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  14. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  15. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Co-author DOI 10.1038/s41419-022-04799-5↗
  16. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  17. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05236-3↗
  18. Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence. Co-author DOI 10.1155/2022/9658890↗
  19. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Co-author DOI 10.3389/fgene.2022.940794↗
  20. Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. Co-author DOI 10.3389/fonc.2022.923982↗
  21. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Co-author DOI 10.3389/fonc.2022.960858↗
  22. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  23. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Last author DOI 10.1016/j.isci.2021.103400↗
  24. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  25. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗
  26. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  27. Huaier extract restrains pancreatic cancer by suppressing Wnt/β-catenin pathway. Co-author DOI 10.1016/j.biopha.2020.110126↗
  28. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. Co-author DOI 10.1016/j.canlet.2019.11.041↗
  29. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor. Co-author DOI 10.1136/rapm-2019-100991↗
  30. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  31. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  32. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  33. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. Co-author DOI 10.3892/or.2020.7600↗
  34. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  35. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Co-author DOI 10.1016/j.csbj.2019.03.016↗
  36. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  37. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Co-author DOI 10.1177/0963689719851772↗
  38. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  39. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  40. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  41. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways. Co-author DOI 10.3892/or.2018.6833↗
  42. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  43. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  44. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  45. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  46. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  47. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Co-author DOI 10.1159/000494547↗
  48. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  49. Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2018.4295↗
  50. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. Co-author DOI 10.3892/ijo.2018.4363↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weikun Qian · 42 shared papers, 2017–2025 · strength 5.07
  2. Zheng Wang · 41 shared papers, 2011–2025 · strength 4.02
  3. Wanxing Duan · 49 shared papers, 2012–2025 · strength 3.44
  4. Zheng Wu · 32 shared papers, 2013–2025 · strength 3.21
  5. Jiguang Ma · 40 shared papers, 2013–2025 · strength 2.94
  6. Cancan Zhou · 25 shared papers, 2016–2025 · strength 2.57
  7. Xuqi Li · 35 shared papers, 2012–2025 · strength 2.07
  8. Ying Xiao · 17 shared papers, 2018–2023 · strength 1.97
  9. Erxi Wu · 35 shared papers, 2011–2022 · strength 1.89
  10. Qinhong Xu · 37 shared papers, 2011–2020 · strength 1.82
  11. Jianjun Lei · 30 shared papers, 2012–2021 · strength 1.76
  12. Zhengdong Jiang · 23 shared papers, 2015–2023 · strength 1.58
  13. Liang Cheng · 18 shared papers, 2017–2020 · strength 1.39
  14. Wei Li · 20 shared papers, 2011–2024 · strength 1.34
  15. Jie Li · 13 shared papers, 2017–2024 · strength 1.34
  16. Liang Han · 15 shared papers, 2013–2025 · strength 1.30
  17. Tao Qin · 11 shared papers, 2018–2022 · strength 1.20
  18. Zeen Zhu · 8 shared papers, 2021–2025 · strength 1.18
  19. Jiantao Mo · 6 shared papers, 2022–2025 · strength 1.11
  20. Yangyang Yue · 8 shared papers, 2020–2024 · strength 1.11
  21. Ke Chen · 14 shared papers, 2016–2022 · strength 1.08
  22. Liankang Sun · 14 shared papers, 2016–2020 · strength 1.06
  23. Liang Han · 17 shared papers, 2011–2022 · strength 1.06
  24. Wunai Zhang · 7 shared papers, 2021–2025 · strength 1.05
  25. Jingtao Gu · 5 shared papers, 2022–2025 · strength 1.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.